Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT.

Blood. 2011 Mar 31;117(13):3585-95. doi: 10.1182/blood-2010-08-301267. Epub 2011 Jan 24.

2.

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ.

Blood. 2015 Feb 26;125(9):1444-51. doi: 10.1182/blood-2014-09-601062. Epub 2014 Dec 12.

3.

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.

Takahashi N, Miura M, Scott SA, Niioka T, Sawada K.

J Hematol Oncol. 2012 May 15;5:23. doi: 10.1186/1756-8722-5-23.

4.

Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.

Fei F, Stoddart S, Groffen J, Heisterkamp N.

Mol Cancer Ther. 2010 May;9(5):1318-27. doi: 10.1158/1535-7163.MCT-10-0069. Epub 2010 Apr 13.

5.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Mar;92(3):401-4.

7.

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, Martinelli G.

Cancer. 2014 Apr 1;120(7):1002-9. doi: 10.1002/cncr.28522. Epub 2013 Dec 30.

8.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

9.

Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.

Okabe S, Tauchi T, Ohyashiki K.

Exp Hematol. 2010 Sep;38(9):765-72. doi: 10.1016/j.exphem.2010.04.017. Epub 2010 May 13.

PMID:
20471447
10.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J.

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

PMID:
19768693
11.

Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Williams RT, den Besten W, Sherr CJ.

Genes Dev. 2007 Sep 15;21(18):2283-7. Epub 2007 Aug 30.

12.

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.

Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N.

Leukemia. 2010 Apr;24(4):813-20. doi: 10.1038/leu.2009.302. Epub 2010 Jan 28.

13.

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, Giagounidis A, Stelljes M, Schmalzing M, Dührsen U, Wunderle L, Serve H, Brück P, Schmidt A, Hoelzer D, Ottmann OG.

Leukemia. 2012 Jul;26(7):1475-81. doi: 10.1038/leu.2012.5. Epub 2012 Jan 9.

PMID:
22230800
14.

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Piccaluga PP, Paolini S, Martinelli G.

Cancer. 2007 Sep 15;110(6):1178-86. Review.

15.

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Ottmann OG, Pfeifer H.

Hematology Am Soc Hematol Educ Program. 2009:371-81. doi: 10.1182/asheducation-2009.1.371.

PMID:
20008223
16.

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G.

Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9.

17.

Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.

Egan DN, Beppu L, Radich JP.

Biol Blood Marrow Transplant. 2015 Jan;21(1):184-9. doi: 10.1016/j.bbmt.2014.09.012. Epub 2014 Oct 6.

18.

[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].

Zhu Y, Pan LQ, Qian SX, Song P, Yu H, Zhang SJ, Ge Z, Hong M, Tian T, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):581-6. doi: 10.7534/j.issn.1009-2137.2013.03.009. Chinese.

PMID:
23815902
19.

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG.

Blood. 2007 Jul 15;110(2):727-34. Epub 2007 Apr 3.

20.

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5507-12. doi: 10.1073/pnas.0800587105. Epub 2008 Mar 26.

Supplemental Content

Support Center